CencoraWBO:ABC -1.69%69 EBIT per Share is €17.60 as of Mar. 2026. GuruFocus rates WBO:ABC with a GF Score™ of 69/100 and a GF Value™ of €259.15 (Fairly Valued). The stock has 1 warning sign investors should review. Among 106 Medical Distribution companies, Cencora ranks better than 74.53% on this metric.
Cencora's EBIT per Share for the
three
months ended in Mar. 2026 was €9.93.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €17.60.
During the past 12 months, the average EBIT per Share Growth Rate of Cencora was 24.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 15.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 12.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 10.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cencora's EBIT per Share or its related term are showing as below:
WBO:ABC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -29.5 Med: 11.1 Max: 25.7
Current: 15.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cencora was 25.70% per year. The lowest was -29.50% per year. And the median was 11.10% per year.
WBO:ABC's 3-Year EBIT Growth Rate is ranked better than 74.53% of 106
companies
in the Medical Distribution industry
Industry Median: 4.1
vs WBO:ABC: 15.60
Cencora's EBIT for the
three
months ended in Mar. 2026 was €1,940 Mil.
Cencora (WBO:ABC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cencora EBIT per Share Related Terms
Cencora EBIT per Share Historical Data
* Premium members only.
The historical data trend for Cencora's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €17.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora (WBO:ABC) has a EBIT per Share of €17.60 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cencora and its competitors. According to the industry distribution chart, Cencora ranks #27 out of 106 companies in the Medical Distribution industry, placing it in the top 25.5%.
Is Cencora's EBIT per Share too high?
Cencora's current EBIT per Share is €17.60. Based on the distribution chart, Cencora ranks #27 out of 106 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Cencora has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's EBIT per Share compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #27 out of 106 companies for EBIT per Share. This puts Cencora in the upper half of its industry. The industry median EBIT per Share is 4.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.10, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cencora and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current EBIT per Share is €17.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €259.15, compared to a current price of €250.00 — trading 3.5% below its estimated fair value. The current EBIT per Share is €17.60. Cencora's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cencora (WBO:ABC), the current EBIT per Share is €17.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be undervalued.
The current stock price of €250.00 is trading 3.5% below its estimated GF Value™ of €259.15.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
EBIT per Share: €17.60
GF Value™: €259.15 vs. price of €250.00 (3.5% below fair value)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
69GF Score
Get the complete analysis for WBO:ABC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 
